1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,700 | 10,500 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 13.08. | Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older | 297 | GlobeNewswire (Europe) | Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and... ► Artikel lesen | |
| 04.08. | Pharming Group N.V.: Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference | 426 | GlobeNewswire (Europe) | Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston... ► Artikel lesen | |
| 30.07. | Oppenheimer cuts Pharming Group stock price target on lowered guidance | 8 | Investing.com | ||
| 30.07. | Oppenheimer senkt Kursziel für Pharming Group nach Prognosekorrektur | 9 | Investing.com Deutsch | ||
| 30.07. | Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure | 1 | Investing.com | ||
| 30.07. | Pharming GAAP EPS of $0.00 misses by $0.06, revenue of $90.2M misses by $9.32M | 4 | Seeking Alpha | ||
| 30.07. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 30.07. | Pharming Group senkt Umsatzprognose für 2026 wegen schwacher Absatzzahlen | 15 | Investing.com Deutsch | ||
| 30.07. | Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use | 999 | GlobeNewswire (Europe) | For investor audiences and media only
Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST revenue was US$72.3 million, a 10% decrease... ► Artikel lesen | |
| 22.07. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 419 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
22.07.2026 / 16:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 16.07. | Pharming Group N.V.: Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30 | 772 | GlobeNewswire (Europe) | Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second... ► Artikel lesen | |
| 04.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 04.06. | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | 492 | GlobeNewswire (Europe) | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| 02.06. | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York | 651 | GlobeNewswire (Europe) | Leiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New... ► Artikel lesen | |
| 28.05. | Pharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of Shareholders | 961 | GlobeNewswire (Europe) | Leiden, the Netherlands, May 28, 2026: Pharming Group ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at... ► Artikel lesen | |
| 23.05. | Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency | 7 | RTTNews | ||
| 22.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 19 | SEC Filings | ||
| 22.05. | Pharming Group N.V.: European Commission grants marketing authorization to Pharming's Joenja (leniolisib) - the first approved treatment for APDS in the European Union | 745 | GlobeNewswire (Europe) | Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3K,) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric... ► Artikel lesen | |
| 13.05. | Pharming Group: Umsatz im Q1 2026 sinkt wegen Herausforderungen bei RUCONEST | 14 | Investing.com Deutsch |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,348 | -1,06 % | Evotec-Aktie: Fällt jetzt die 3,00 €-Marke? | Die Evotec-Aktie befindet sich weiterhin tief im Abwärtstrend und notiert inzwischen rund -93% unter ihrem Allzeithoch. Damit hat die Biotech-Aktie über Jahre hinweg massiv an Wert verloren. Gleichzeitig... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| IDEXX LABORATORIES | 473,00 | -1,25 % | IDEXX Labs Reports Higher Q2 Profit On Strong Revenue Growth; Lifts FY Earnings Outlook; Stock Up | WASHINGTON (dpa-AFX) - IDEXX Laboratories Inc. (IDXX), a developer of veterinary diagnostics, software and water testing solutions, reported higher second-quarter profit, driven by strong revenue... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ATAIBECKLEY | 6,300 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 196,20 | -0,20 % | UBS stuft Sartorius Stedim Biotech auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Sartorius Stedim von 220 auf 260 Euro angehoben und die Aktien von "Neutral" auf "Buy" hochgestuft. Matthew Weston lobte bei... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-1,02 %) liegt der Kurs bei 9,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.